Ascendis Pharma A/S
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Ascendis Pharma (ASND) authorized a $400M share buyback. Q2 2025 saw €315M product revenue, up 105% YoY, with €220M operating profit. Cash reserves grew to €812M. Buyback is discretionary, dependent on market conditions. YORVIPATH drove most revenue, while SKYTROFA and YUVIWEL contributed less. Costs increased due to expansion and R&D.
Ascendis Pharma (ASND) and BioMarin (BMRN) settled a patent dispute, with ASND paying BMRN royalties on Yuviwel sales. ASND rose 6% and BMRN 1%. Analysts adjusted targets but kept ratings unchanged, citing legal clarity and growth prospects.
Ascendis Pharma (ASND) will regain exclusive rights to metabolic and cardiovascular TransCon products, including TransCon Semaglutide, after ending its collaboration with Novo Nordisk (NVO). The move grants ASND more control but also shifts development costs and risks. ASND plans to initiate multiple programs, but clinical success and differentiation remain uncertain.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ASND (Ascendis Pharma A/S). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent ASND coverage spans corporate actions, financial news and market movers.
In the last 30 days, ASND insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($873K). The most active reporter was HOLTUG LARS with 1 filing.
Potential upward pressure on ASND stock as buyback can support price and signal confidence.
Settlement removes legal cloud and creates a revenue stream, likely supporting short‑term upside.
Regaining rights could increase upside if development succeeds, but also raises cost and risk exposure.
The buyback authorization caused a sharp sell‑off as investors reassessed valuation.
The partnership termination removes a large partner’s backing, increasing execution risk and prompting a sharp sell‑off.
AlphAI scores every news story that mentions ASND with an AI model for sentiment and relevance, and aggregates insider trades from Ascendis Pharma A/S's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ascendis Pharma (ASND) authorized a $400M share buyback. Q2 2025 saw €315M product revenue, up 105% YoY, with €220M operating profit. Cash reserves grew to €812M. Buyback is discretionary, dependent on market conditions. YORVIPATH drove most revenue, while SKYTROFA and YUVIWEL contributed less. Costs increased due to expansion and R&D.
2 min readAscendis Pharma (ASND) and BioMarin (BMRN) settled a patent dispute, with ASND paying BMRN royalties on Yuviwel sales. ASND rose 6% and BMRN 1%. Analysts adjusted targets but kept ratings unchanged, citing legal clarity and growth prospects.
2 min readAscendis Pharma (ASND) will regain exclusive rights to metabolic and cardiovascular TransCon products, including TransCon Semaglutide, after ending its collaboration with Novo Nordisk (NVO). The move grants ASND more control but also shifts development costs and risks. ASND plans to initiate multiple programs, but clinical success and differentiation remain uncertain.
2 min readAscendis Pharma (ASND) fell 13% to $230.28 after authorizing a $400M share repurchase program. The stock traded between $230.18 and $257.53 with high volume. Repurchases may occur via various methods, subject to market conditions. The 52-week range is $186.05 to $282.15.
1 min readAscendis Pharma (ASND) fell 10.9% after ending a metabolic and cardiovascular collaboration, reverting rights to TransCon semaglutide. Analysts downgraded the stock, despite a $400M share buyback plan. Investors may be reassessing the program's value and development path.
2 min readAnalysts downgraded several stocks: HSBC cut Banco Santander Brasil (BSBR) to Hold with a $6.2 target; Rosenblatt downgraded Ribbon Communications (RBBN) to Neutral with a $2.2 target; Citizens downgraded Cellectis (CLLS) to Market Perform; Barclays downgraded Scholar Rock (SRRK) to Equal-Weight with a $58 target; Raymond James downgraded Ascendis Pharma (ASND) to Outperform with a $287 target.
1 min readAscendis Pharma (ASND) announced a $400M share repurchase program on September 14, 2026. The buyback may occur through open-market purchases or structured transactions, with flexibility to adjust or terminate. Execution depends on market conditions, share price, and other factors, with potential impact on earnings per share and stock price, though broader risks remain.
1 min readRaymond James downgraded Ascendis Pharma from Strong Buy to Outperform. The company's stock is currently trading at $231.34, down 12.68% over 5 days. Ascendis Pharma presented at the Morgan Stanley 24th Annual Global Healthcare Conference.
1 min readAscendis Pharma (ASND) announced it will regain exclusive rights to develop and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity, from Novo Nordisk. The termination of their collaboration agreement means all licenses, including for TransCon Semaglutide, revert to Ascendis, with no ongoing financial obligations between the parties. The company highlighted uncertainties related to regulatory approvals and market acceptance.
2 min readAscendis Pharma regained rights to an obesity drug and announced a $400 million share buyback. The company presented at the Morgan Stanley 24th Annual Global Healthcare Conference. Its stock is down 12.68% over 5 days.
1 min read
